Tri-Maxx

Tri-Maxx is a three-layer fenestrated perinatal tissue allograft derived from human placental membrane, specifically incorporating the amnion, intermediate layer, and chorion. Developed by Samaritan Biologics, it is designed as an advanced wound therapy for chronic, non-healing wounds such as diabetic foot ulcers. The allograft serves as a biological scaffold, providing a complex extracellular matrix (ECM) rich in collagen, growth factors, and cytokines that facilitate cellular migration, proliferation, and tissue regeneration. The fenestrations (perforations) in the graft allow for the drainage of wound exudate while maintaining a selective barrier against the environment. Tri-Maxx is regulated as a Human Cell, Tissue, and Cellular and Tissue-Based Product (HCT/P) under Section 361 of the Public Health Service Act and is typically applied weekly in conjunction with standard wound care to promote complete wound closure.

Brand names

Tri-Maxx

Other names

three-layer fenestrated perinatal tissue allografthuman placental membrane allograft